克林沙星对革兰氏阳性菌和阴性菌的比较活性。
Comparative activities of clinafloxacin against gram-positive and -negative bacteria.
作者信息
Ednie L M, Jacobs M R, Appelbaum P C
机构信息
Department of Pathology, Hershey Medical Center, Pennsylvania 17033, USA.
出版信息
Antimicrob Agents Chemother. 1998 May;42(5):1269-73. doi: 10.1128/AAC.42.5.1269.
Abstract
Activities of clinafloxacin, ciprofloxacin, levofloxacin, sparfloxacin, trovafloxacin, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, ceftazidime, and imipenem against 354 ciprofloxacin-susceptible and -intermediate-resistant organisms were tested by agar dilution. Clinafloxacin yielded the lowest quinolone MICs (< or = 0.5 microg/ml against ciprofloxacin-susceptible organisms and < or = 16.0 microg/ml against ciprofloxacin-intermediate-resistant organisms) compared to those of levofloxacin, trovafloxacin, and sparfloxacin. Ceftazidime, piperacillin alone or combined with tazobactam, trimethoprim-sulfamethoxazole, and imipenem usually yielded higher MICs against ciprofloxacin-resistant strains.
摘要
采用琼脂稀释法检测了克林沙星、环丙沙星、左氧氟沙星、司帕沙星、曲伐沙星、哌拉西林、哌拉西林 - 他唑巴坦、甲氧苄啶 - 磺胺甲恶唑、头孢他啶和亚胺培南对354株环丙沙星敏感及中介耐药菌的活性。与左氧氟沙星、曲伐沙星和司帕沙星相比，克林沙星产生的喹诺酮类最低抑菌浓度最低（对环丙沙星敏感菌≤0.5微克/毫升，对环丙沙星中介耐药菌≤16.0微克/毫升）。头孢他啶、单独使用的哌拉西林或与他唑巴坦联用、甲氧苄啶 - 磺胺甲恶唑和亚胺培南对环丙沙星耐药菌株通常产生较高的最低抑菌浓度。
相似文献
1
Comparative activities of clinafloxacin against gram-positive and -negative bacteria.克林沙星对革兰氏阳性菌和阴性菌的比较活性。
Antimicrob Agents Chemother. 1998 May;42(5):1269-73. doi: 10.1128/AAC.42.5.1269.
2
Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.曲伐沙星单独及与其他药物联合应用对革兰阴性非发酵菌的比较活性
Antimicrob Agents Chemother. 1997 Jul;41(7):1475-81. doi: 10.1128/AAC.41.7.1475.
3
In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.克林沙星、曲伐沙星和环丙沙星的体外活性
J Antimicrob Chemother. 1997 Aug;40(2):205-11. doi: 10.1093/jac/40.2.205.
4
Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem.非铜绿假单胞菌革兰氏阴性非发酵菌对环丙沙星、氧氟沙星、左氧氟沙星、D-氧氟沙星、司帕沙星、头孢他啶、哌拉西林、哌拉西林-他唑巴坦、甲氧苄啶-磺胺甲恶唑和亚胺培南的敏感性。
Antimicrob Agents Chemother. 1996 Mar;40(3):772-5. doi: 10.1128/AAC.40.3.772.
5
Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.司帕沙星暴露后脆弱拟杆菌对氟喹诺酮类药物的耐药性
Antimicrob Agents Chemother. 1999 Sep;43(9):2251-5. doi: 10.1128/AAC.43.9.2251.
6
In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.环丙沙星、左氧氟沙星、洛美沙星、氧氟沙星、培氟沙星、司帕沙星和曲伐沙星对呼吸道感染革兰氏阳性和革兰氏阴性病原体的体外活性。
J Antimicrob Chemother. 1997 Sep;40(3):427-31. doi: 10.1093/jac/40.3.427.
7
Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals.克林沙星与其他九种化合物针对美国医院2000株当代临床分离株的比较活性。
Diagn Microbiol Infect Dis. 1999 Sep;35(1):81-8. doi: 10.1016/s0732-8893(99)00020-6.
8
Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high.克林沙星单独及与其他化合物联合使用时，对45种克林沙星最低抑菌浓度较高的革兰氏阳性和阴性菌的活性。
Antimicrob Agents Chemother. 1999 Sep;43(9):2295-8. doi: 10.1128/AAC.43.9.2295.
9
Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.曲伐沙星、环丙沙星、氧氟沙星及广谱β-内酰胺类药物对需氧血培养分离菌株的体外活性比较
Zentralbl Bakteriol. 1998 Dec;288(4):509-18. doi: 10.1016/s0934-8840(98)80070-4.
10
In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.曲伐沙星及其他五种氟喹诺酮类药物的体外抗菌活性
Chemotherapy. 1998 Mar-Apr;44(2):85-93. doi: 10.1159/000007097.
引用本文的文献
1
Ciprofloxacin-resistant Escherichia coli in hospital wastewater of Bangladesh and prediction of its mechanism of resistance.孟加拉国医院废水中的环丙沙星耐药大肠杆菌及其耐药机制预测。
World J Microbiol Biotechnol. 2012 Mar;28(3):827-34. doi: 10.1007/s11274-011-0875-3. Epub 2011 Sep 9.
2
Population pharmacokinetics of clinafloxacin in healthy volunteers and patients with infections: experience with heterogeneous pharmacokinetic data.克林沙星在健康志愿者和感染患者中的群体药代动力学：异质性药代动力学数据的经验
Clin Pharmacokinet. 2001;40(4):307-15. doi: 10.2165/00003088-200140040-00006.
3
Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.新型氟喹诺酮类药物对耐环丙沙星肺炎链球菌的活性。
Antimicrob Agents Chemother. 2001 Jun;45(6):1654-9. doi: 10.1128/AAC.45.6.1654-1659.2001.
4
In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci.六种喹诺酮类药物的体外活性及金黄色葡萄球菌和凝固酶阴性葡萄球菌的耐药机制
Antimicrob Agents Chemother. 2001 May;45(5):1553-7. doi: 10.1128/AAC.45.5.1553-1557.2001.
5
Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections.环丙沙星与亚胺培南/西司他丁治疗腹腔内感染的临床试验结果。
Ann Surg. 2001 Jan;233(1):79-87. doi: 10.1097/00000658-200101000-00013.
6
In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.肺炎链球菌对克林沙星、环丙沙星和曲伐沙星的体外耐药性选择
Antimicrob Agents Chemother. 2000 Oct;44(10):2740-6. doi: 10.1128/AAC.44.10.2740-2746.2000.
7
Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.1997 - 1998呼吸道疾病流行季期间，来自全球监测研究的对不同氟喹诺酮类药物敏感性降低的肺炎链球菌临床分离株中gyrA、gyrB、parC和parE基因突变的发生率。
Antimicrob Agents Chemother. 2000 Feb;44(2):462-6. doi: 10.1128/AAC.44.2.462-466.2000.
8
Activity of newer fluoroquinolones in vitro against gram-positive bacteria.新型氟喹诺酮类药物对革兰氏阳性菌的体外活性。
Drugs. 1999;58 Suppl 2:23-8. doi: 10.2165/00003495-199958002-00005.
9
Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high.克林沙星单独及与其他化合物联合使用时，对45种克林沙星最低抑菌浓度较高的革兰氏阳性和阴性菌的活性。
Antimicrob Agents Chemother. 1999 Sep;43(9):2295-8. doi: 10.1128/AAC.43.9.2295.
10
Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.新型喹诺酮类药物在腹腔内感染治疗中的应用：聚焦于克林沙星
Infection. 1999 May-Jun;27(3):166-72. doi: 10.1007/BF02561522.
本文引用的文献
1
The in-vitro activity of ceftazidime compared with that of other cephalosporins.头孢他啶与其他头孢菌素的体外活性比较。
J Antimicrob Chemother. 1981 Sep;8 Suppl B:47-51. doi: 10.1093/jac/8.suppl_b.47.
2
In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.克林沙星、曲伐沙星和环丙沙星的体外活性
J Antimicrob Chemother. 1997 Aug;40(2):205-11. doi: 10.1093/jac/40.2.205.
3
Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.曲伐沙星单独及与其他药物联合应用对革兰阴性非发酵菌的比较活性
Antimicrob Agents Chemother. 1997 Jul;41(7):1475-81. doi: 10.1128/AAC.41.7.1475.
4
Comparative therapeutic efficacy of clinafloxacin in leucopenic mice.克林沙星在白细胞减少小鼠中的比较治疗效果。
J Antimicrob Chemother. 1997 Feb;39(2):273-6. doi: 10.1093/jac/39.2.273.
5
The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects.健康受试者中克林沙星（CI-960）的耐受性和药代动力学
J Antimicrob Chemother. 1996 Dec;38(6):1023-9. doi: 10.1093/jac/38.6.1023.
6
Efficacy of quinolones in preventing Staphylococcus aureus-induced abscess in mice.喹诺酮类药物在预防小鼠金黄色葡萄球菌诱导脓肿中的疗效。
J Antimicrob Chemother. 1995 Sep;36(3):551-5. doi: 10.1093/jac/36.3.551.
7
The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci.克林沙星与其他抗菌药物对万古霉素敏感和耐药肠球菌的体外比较活性。
Chemotherapy. 1996 Jul-Aug;42(4):235-9. doi: 10.1159/000239449.
8
In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens.司帕沙星与现有抗微生物药物对呼吸道病原体的体外活性比较。
J Antimicrob Chemother. 1996 May;37 Suppl A:1-18. doi: 10.1093/jac/37.suppl_a.1.
9
In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci.克林沙星、CI-990（PD 131112）和PD 138312对肠球菌的体外和体内活性
Antimicrob Agents Chemother. 1995 Sep;39(9):2123-7. doi: 10.1128/AAC.39.9.2123.
10
Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.使用环丙沙星耐药菌预测菌组对克林沙星与环丙沙星、氟罗沙星、氧氟沙星和司帕沙星进行交叉耐药性分析。
J Antimicrob Chemother. 1995 Aug;36(2):431-4. doi: 10.1093/jac/36.2.431.
Zotero 插件